Form D · Biotechnology
GevRx Nutraceuticals, Inc.
Staten Island, NY · CIK 0002156105
Offering snapshot reported Sep 18, 2026 · SEC filing
- Reported sold
- $300K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2026 | Initial | $300,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598108
The total offering amount reflects the gross proceeds to be received assuming sale of 300,000 shares of common stock, par value $0.001 per share, of the Company, at a price of $10.00 per share.
Source: Form D, filed Sep 18, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael J. Betley, Ph.D. | Executive |
| James Thomas Christopher | Director, Executive |
| Mary Stephen Esposito | Director |
| Dylan Tyler Spiel | Executive |
| Douglas Spiel, M.D. | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Marble Loop Suite 2 A
Staten Island, NY, 10309
Phone: (917) 939-9424
Staten Island, NY, 10309
Phone: (917) 939-9424